Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

37.67
+0.37421.00%
Post-market: 37.44-0.2342-0.62%16:10 EDT
Volume:724
Turnover:27.15K
Market Cap:19.78M
PE:- -
High:37.67
Open:37.44
Low:37.44
Close:37.30
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.75
T/O Rate:0.14%
Dividend:0.11
Dividend Rate:0.30%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

Top Midday Stories: Stocks Fall, Oil Rises Amid Renewed Fighting in Middle East; Utility Shares Fall After California Wildfire Legislation

MT Newswires Live
·
Aug 31

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

MT Newswires Live
·
Aug 31

Dow Jones Top Company Headlines at 11 am ET: GameStop Sees Higher Profit as eBay Investment Offsets Lower Sales | SLB ...

Dow Jones
·
Aug 31

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Aug 31

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Acotec Swings to Loss on R&D Surge and U.S. Trial Impairment

TIPRANKS
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Aug 31

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Aug 31

Guangdong Hybribio Biotech's Subsidiary Secures In Vitro Diagnostic Device Registration Certificate

Stock News
·
Aug 31

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

TIPRANKS
·
Aug 31

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

TIPRANKS
·
Aug 31

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.
·
Aug 30
More